DEA Sets June 2026 Cannabis Rescheduling Hearing Date
Federal agency confirms formal hearing to review marijuana's Schedule I classification, marking critical juncture for industry tax relief and banking access.
The Drug Enforcement Administration confirms it will hold a formal hearing on June 29, 2026, to evaluate reclassifying marijuana from Schedule I to Schedule III under the Controlled Substances Act. This administrative proceeding represents the most concrete federal action toward cannabis reform since the Controlled Substances Act took effect in 1970, potentially reshaping the entire industry's financial landscape.
Rescheduling to Schedule III would eliminate the punitive 280E tax provision that currently prevents cannabis companies from deducting standard business expenses. Multi-state operators like Curaleaf Holdings, Green Thumb Industries, and Cresco Labs face effective tax rates exceeding 70% under current federal classification. Relief from 280E could boost industry-wide EBITDA margins by 15-25 percentage points, according to cannabis equity research.
The hearing also opens pathways for traditional banking services that remain largely inaccessible due to federal prohibition. Major financial institutions avoid cannabis clients to prevent potential federal penalties, forcing operators to conduct business primarily in cash. Schedule III classification would likely accelerate institutional banking relationships and reduce operational costs across the supply chain.
Investor sentiment around rescheduling has driven significant volatility in cannabis equities over the past two years. The AdvisorShares Pure US Cannabis ETF has experienced multiple rallies exceeding 30% on rescheduling speculation, followed by sharp corrections when timelines proved optimistic. The confirmed hearing date provides concrete timeline visibility that markets have lacked during the prolonged regulatory review process.
While Schedule III represents meaningful progress, it maintains federal control over cannabis as a controlled substance, unlike full descheduling that advocacy groups prefer. The hearing format allows public comment and industry input, but the DEA retains final authority over any classification changes. Cannabis operators continue expanding state-level operations while preparing for potential federal tax advantages that could fundamentally alter industry profitability metrics.